title: Effect of Mediterranean diet with and without weight loss on apolipoprotein B100 metabolism in men with metabolic syndrome.
abstract: OBJECTIVE
  To assess the effect of a Mediterranean diet (MedDiet) with and without weight loss (WL) on apolipoprotein B100 (apoB100) metabolism in men with metabolic syndrome.
  
  
  RESULTS
  The diet of 19 men with metabolic syndrome (age, 24-62 years) was first standardized to a North American isoenergetic control diet for 5 weeks, followed by an isoenergetic MedDiet for an additional 5 weeks under full-feeding conditions (MedDiet-WL). Participants next underwent a 20-week supervised WL program under free-living conditions (-10.2 ± 2.9% body weight; P<0.01) and finally consumed the MedDiet (5 weeks) under weight-stabilizing feeding conditions (MedDiet+WL). In vivo kinetic of apoB100 was assessed in the fasted state at the end of the 3 controlled diets using a bolus of D3-leucine. Compared with the control diet, MedDiet-WL reduced low-density lipoprotein (LDL)-apoB100 pool size (-14.2%, P<0.01) primarily through an increase in LDL-apoB100 fractional catabolic rate (+30.4%, P=0.02) and increased LDL particle size (P<0.01) but had no effect on very-LDL (VLDL)-apoB100 pool size or triglyceride concentrations, despite a significant increase in VLDL-apoB100 fractional catabolic rate (+25.6%; P=0.03). MedDiet+WL had no further effect on LDL-apoB100 pool size and fractional catabolic rate but further increased LDL particle size and reduced VLDL-apoB100 pool size versus the control diet primarily through an increase in VLDL-apoB100 fractional catabolic rate (+30.7%; P<0.01).
  
  
  CONCLUSIONS
  Consumption of MedDiet increases LDL size and reduces LDL-apoB100 concentrations primarily by increasing the catabolism of LDL even in the absence of WL in men with metabolic syndrome. MedDiet seems to have a trivial effect on VLDL concentrations and kinetics unless accompanied by significant WL.
  http://www.clinicaltrials.gov. Unique identifier: NCT00988650.
authors.affiliation: From the Institute of Nutrition and Functional Foods, Laval University, Quebec City, Quebec, Canada (C.R., P.C., A.J.T., S.D., A.C., B.L.); Metabolic Research Centre, School of Medicine and Pharmacology, University of Western Australia, Perth, Western Australia, Australia (E.M.M.O.); and Cardiovascular Nutrition Laboratory, Tufts University, Boston, MA (A.H.L.).
authors.forename: Caroline
authors.initials: C
authors.lastname: Richard
authors.forename: Patrick
authors.initials: P
authors.lastname: Couture
authors.forename: Esther M M
authors.initials: EM
authors.lastname: Ooi
authors.forename: André J
authors.initials: AJ
authors.lastname: Tremblay
authors.forename: Sophie
authors.initials: S
authors.lastname: Desroches
authors.forename: Amélie
authors.initials: A
authors.lastname: Charest
authors.forename: Alice H
authors.initials: AH
authors.lastname: Lichtenstein
authors.forename: Benoît
authors.initials: B
authors.lastname: Lamarche
mesh_terms: D000328:Adult; D053299:Apolipoprotein B-100 / Q000097:blood*; D015415:Biomarkers / Q000097:blood; D038441:Diet, Mediterranean; D002149:Energy Intake; D006801:Humans; D007700:Kinetics; D008075:Lipoproteins, HDL / Q000097:blood; D008077:Lipoproteins, LDL / Q000097:blood; D008297:Male; D024821:Metabolic Syndrome / Q000097:blood / Q000175:diagnosis / Q000178:diet therapy*; D008875:Middle Aged; D008954:Models, Biological; D010316:Particle Size; D011792:Quebec; D016896:Treatment Outcome; D015431:Weight Loss; D055815:Young Adult
chemical_list: D053299:Apolipoprotein B-100; D015415:Biomarkers; D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL
keywords: apolipoprotein B100; diet, Mediterranean; metabolic syndrome; weight loss